Volume 151, Issue 3, Pages (March 2017)

Slides:



Advertisements
Similar presentations
Volume 32, Issue 1, Pages (July 1957)
Advertisements

Volume 145, Issue 6, Pages (June 2014)
Tell-tale Telangiectasias
Colloquium on Therapy of Right Heart Failure
Environmental Causes of Cancer of the Lung Other Than Tobacco Smoke
Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation  Bridget.
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
When to Be Rash About a Fever and Headache
Management of Myositis-Related Interstitial Lung Disease
Epidemiology and Treatment of Lung Cancer in Seattle
Robert Pickering, M.D, Fernando J. Martinez, M.D  CHEST 
Hyperbaric Oxygenation in Cardiac and Pulmonary Disease
Air Pollution and Chest Disease
Navin K. Jain, MD, Thiam H. Lie, MD, FCCP  CHEST 
Single-Breath Washout Tests to Assess Small Airway Disease in COPD
Fever, Skin Eruption, Low Serum Gammaglobulin in a Child with Leukemia
Volume 148, Issue 5, Pages (November 2015)
Volume 142, Issue 1, Pages (July 2012)
Volume 151, Issue 3, Pages (March 2017)
Volume 141, Issue 2, Pages (February 2012)
Volume 152, Issue 5, Pages (November 2017)
The Lung Cancer Stage Page
Volume 153, Issue 1, Pages (January 2018)
Arterial Line or Cuff BP?
Spread the Word About CHEST in 2018
Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.
Krishman. Padmanabhan, M.D., F.C.C.P., Santi R. Dhar, M.D., F.C.C.P 
COUNTERPOINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? No  Joshua J. Mooney, MD, Harold R. Collard,
Volume 153, Issue 3, Pages e41-e43 (March 2018)
Volume 79, Issue 2, Pages (February 1981)
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Sleep Apnea, Hypothyroidism and Pulmonary Edema
Weekday and Survival After Pulmonary Resections for Lung Cancer
Sundeep Salvi, MD, DNB, PhD, FCCP, Peter J. Barnes, DM, FCCP  CHEST 
Volume 104, Issue 1, Pages 1-2 (July 1993)
Imaging for the Management of Community-Acquired Pneumonia
Spread the Word About CHEST in 2015
Volume 154, Issue 5, Pages (November 2018)
Sporadic Obliterative Bronchiolitis: Case Series and Systematic Review of the Literature  Sean J. Callahan, MD, Andrew Vranic, MD, Lucia Flors, MD, Michael.
Volume 154, Issue 2, Pages (August 2018)
A Patient With Chest Pain and Hyperacute T Waves
Brahms' Lullaby Revisited
Volume 103, Issue 6, Pages (June 1993)
Chemical Pneumonitis Due to Exposure to Bromine Compounds
Evolution in Reimbursement for Sleep Studies and Sleep Centers
COUNTERPOINT: Is It Time for Pulmonary Concierge Practices? Not Yet
Survival After an ICU Hospitalization for Pulmonary Hypertension
Volume 152, Issue 6, Pages (December 2017)
Giants in Chest Medicine: Professor Atul C. Mehta, MBBS, FCCP
Bedside Calibration Of Pulmonary Artery Catheters
Invasive Pulmonary Aspergillosis
Pulmonary Manifestations in a Case of Multiple Myeloma
A 7-Year-Old Boy With Sudden Onset of Loud Snoring
Do CIs Give You Confidence?
A Man in His 70s Presenting With Chest Pain and Hematuria
A Single Nasal Prong for Continuous Oxygen Therapy
Myocardial Sarcoidosis Unresponsive to Steroids
Ribavirin in Desquamative Interstitial Pneumonia
Volume 150, Issue 4, Pages (October 2016)
Jason Chertoff, MD, MPH, Paul Stevenson, MD, Hassan Alnuaimat, MD 
Volume 133, Issue 4, Pages (April 2008)
Use of Endobronchial Ultrasound for Bedside Diagnosis of Acute Pulmonary Embolism in a Critically Ill Patient  Colleen L. Channick, MD, FCCP, Richard.
In Reply: Lymphangiomyomatosis
Lung Density in Extremely Large Healthy Lungs
Arterial Line or Cuff BP?
New Members of the Editorial Board
Rebuttal From Dr Kollef
Chronic Pseudomonas aeruginosa Pneumonia in a Normal Adult
Lung Volume Reduction Surgery in the United States From 2007 to 2013
Mohmmed Algamdi, MBBS, Mohsen Sadatsafavi, PhD, Jolene H
Presentation transcript:

Volume 151, Issue 3, Pages 619-625 (March 2017) Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis  Julie Morisset, MD, Kerri A. Johannson, MD, Eric Vittinghoff, PhD, Carlos Aravena, MD, Brett M. Elicker, MD, Kirk D. Jones, MD, Charlene D. Fell, MD, Helene Manganas, MD, Bruno-Pierre Dubé, MD, Paul J. Wolters, MD, Harold R. Collard, MD, FCCP, Christopher J. Ryerson, MD, Brett Ley, MD  CHEST  Volume 151, Issue 3, Pages 619-625 (March 2017) DOI: 10.1016/j.chest.2016.10.029 Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 1 Cohort formation. AZA = azathioprine; CHUM = Centre Hospitalier de l’Université de Montréal; HP = hypersensitivity pneumonitis; MMD = multidisciplinary discussion; MMF = mycophenolate mofetil; PFT = pulmonary function test; UBC = University of British Columbia; UCalgary = University of Calgary; UCSF = University of California, San Francisco. CHEST 2017 151, 619-625DOI: (10.1016/j.chest.2016.10.029) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 2 Mixed-effects model estimates for FVC % predicted and Dlco % predicted before and after initiation of mycophenolate or azathioprine. The gray shading indicates the 95% CI. Dlco = diffusion capacity of the lung for carbon monoxide. See Figure 1 legend for expansion of other abbreviations. CHEST 2017 151, 619-625DOI: (10.1016/j.chest.2016.10.029) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 3 Mixed-effects model estimates for FVC % predicted and Dlco % predicted before and after initiation of mycophenolate. The gray shading indicates the 95% CI. See Figure 1 and 2 legends for expansion of abbreviations. CHEST 2017 151, 619-625DOI: (10.1016/j.chest.2016.10.029) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 4 Mixed-effects model estimates for FVC % predicted and Dlco % predicted before and after initiation of azathioprine. The gray shading indicates the 95% CI. See Figure 1 and 2 legends for expansion of abbreviations. CHEST 2017 151, 619-625DOI: (10.1016/j.chest.2016.10.029) Copyright © 2016 American College of Chest Physicians Terms and Conditions